Potential impact of AUSFTA on Australia's blood supply

Wolfgang Frenzel
Med J Aust 2007; 186 (8): . || doi: 10.5694/j.1326-5377.2007.tb00983.x
Published online: 16 April 2007

In reply: I would like to respond to the letter by Kennedy et al regarding the passive transfer of human T-lymphotropic virus (HTLV) antibodies following Octagam (intravenous immunoglobulin [IVIg]) administration.

  • Wolfgang Frenzel

  • Octapharma, Vienna, Austria

Competing interests:

Octapharma is the manufacturer of Octagam. I am employed by Octapharma in the role of International Medical Director.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.